Abstract
High-dose chemotherapy (HDCT) plus autologous hematopoietic stem-cell transplantation (HSCT) has been explored in several solid tumors in the attempt to prevent and/or overcome tumor-cell chemoresistance, based on in vitro evidence of a “dose-response” effect. Preliminary encouraging results from nonrandomized trials, led to an increased use of this strategy in the 1990s. Since the end of the nineties, the fraudulent nature of initial reports in breast cancer, the failure of positive prospective randomized trials, HDCT-related toxicities, determined a dramatic decline of interest in this approach. Loss of accrual in ongoing randomized studies was the first consequence, causing the current unavailability of optimal information. From the review of available published data, the use of HDCT with autologous HSCT may improve tumor response rates and/or possibly progression-free survival, especially in some selected patient subgroups. However, this strategy did not demonstrate in almost all cases to produce significantly higher cure rates than standard-dose chemotherapy. Well-designed randomized studies and future strategies integrating HDCT with concomitant and/or subsequent anti-tumor therapies targeted against the residual disease might be suggested in clinically and biologically selected patients.
Keywords: High-dose chemotherapy, autologous hemopoietic stem-cell transplantation, solid tumor, dose intensity, doseresponse, breast cancer
Current Stem Cell Research & Therapy
Title: High-Dose Chemotherapy Followed by Autologous Hematopoietic Stem-Cell Transplantation for the Treatment of Solid Tumors in Adults: A Critical Review
Volume: 2 Issue: 1
Author(s): Giuseppe Luigi Banna, Matteo Simonelli and Armando Santoro
Affiliation:
Keywords: High-dose chemotherapy, autologous hemopoietic stem-cell transplantation, solid tumor, dose intensity, doseresponse, breast cancer
Abstract: High-dose chemotherapy (HDCT) plus autologous hematopoietic stem-cell transplantation (HSCT) has been explored in several solid tumors in the attempt to prevent and/or overcome tumor-cell chemoresistance, based on in vitro evidence of a “dose-response” effect. Preliminary encouraging results from nonrandomized trials, led to an increased use of this strategy in the 1990s. Since the end of the nineties, the fraudulent nature of initial reports in breast cancer, the failure of positive prospective randomized trials, HDCT-related toxicities, determined a dramatic decline of interest in this approach. Loss of accrual in ongoing randomized studies was the first consequence, causing the current unavailability of optimal information. From the review of available published data, the use of HDCT with autologous HSCT may improve tumor response rates and/or possibly progression-free survival, especially in some selected patient subgroups. However, this strategy did not demonstrate in almost all cases to produce significantly higher cure rates than standard-dose chemotherapy. Well-designed randomized studies and future strategies integrating HDCT with concomitant and/or subsequent anti-tumor therapies targeted against the residual disease might be suggested in clinically and biologically selected patients.
Export Options
About this article
Cite this article as:
Luigi Banna Giuseppe, Simonelli Matteo and Santoro Armando, High-Dose Chemotherapy Followed by Autologous Hematopoietic Stem-Cell Transplantation for the Treatment of Solid Tumors in Adults: A Critical Review, Current Stem Cell Research & Therapy 2007; 2 (1) . https://dx.doi.org/10.2174/157488807779316964
DOI https://dx.doi.org/10.2174/157488807779316964 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biotechnological Engineering of Heparin/Heparan Sulphate: A Novel Area of Multi-Target Drug Discovery
Current Pharmaceutical Design Hardware and Software Approaches to Multi-Modality Imaging
Current Medical Imaging Recent Patents on New Steroid Agents Targeting the Steroidogenesis for Endocrine Cancer Treatments
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Early Development of Sea Urchin P.lividus Under Static (6 mT) and Pulsed Magnetic Fields (15 and 72 Hz)
Current Chemical Biology A Review of Nanocarrier-Based CNS Delivery Systems
Current Drug Delivery Vitamin D and Cancer Mortality: Systematic Review of Prospective Epidemiological Studies
Anti-Cancer Agents in Medicinal Chemistry 18F-fluoro-deoxy-D-glucose PET/CT in Establishing the Relationship Between the Metabolic Activity of Aorta and Iliac Artery Aneurysms in Cancer Patients
Current Medical Imaging Choosing between Targeted Therapies for Rheumatoid Arthritis Patients: The Oncology Perspective
Current Rheumatology Reviews Telomerase Inhibitors: Potential Anticancer Agents
Mini-Reviews in Organic Chemistry The Multifaceted Activities of Mammalian Defensins
Current Pharmaceutical Design Inflammatory Bowel Disease: New Therapeutic Options in the Post Anti-TNFα Era
Current Drug Metabolism Translocator Protein Ligands as Promising Therapeutic Tools for Anxiety Disorders
Current Medicinal Chemistry Genomics of Chronic Obstructive Pulmonary Disease (COPD); Exploring the SNPs of Protease-Antiprotease Pathway
Current Genomics Cellular Iron Homeostasis and Therapeutic Implications of Iron Chelators in Cancer
Current Pharmaceutical Biotechnology Can Breast Cancer Stem Cells Evade the Immune System?
Current Medicinal Chemistry Meet Our Editorial Board Member:
Current Medicinal Chemistry Aquaporin and Vascular Diseases
Current Neuropharmacology ACO Inspired Computer-aided Detection/Diagnosis (CADe/CADx) Model for Medical Data Classification
Recent Patents on Computer Science Molecular Targeting of Breast Cancer: Molecular Imaging and Therapy
Current Pharmaceutical Biotechnology Pharmacogenomics of the Human ATP-Binding Cassette Transporter ABCG2
Current Pharmacogenomics